Kushner Pamela
University of California, Irvine, CA, USA.
Kushner Wellness Center, 3745 Long Beach Blvd, Suite 100, Long Beach, CA 90807, USA.
Womens Health (Lond). 2016 Jun;12(3):379-88. doi: 10.2217/whe-2016-0001. Epub 2016 Feb 29.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as canagliflozin, are used in patients with Type 2 diabetes mellitus (T2DM). In clinical studies, canagliflozin significantly reduced A1C, bodyweight and blood pressure, and was generally well tolerated with no increased risk of hypoglycemia. Most common adverse effects observed were genital mycotic infections and urinary tract infections, and increased urination. Approximately 10% of women treated with canagliflozin experienced a genital mycotic infection compared with 3% treated with placebo; those with a prior history were at greater risk. Approximately 9% of women treated with canagliflozin reported a urinary tract infection compared with 7% treated with placebo. Most adverse events were considered mild to moderate in intensity and responded to standard therapy. Treatment with canagliflozin was effective and generally well tolerated in both women (and men) with T2DM.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂，如卡格列净，用于2型糖尿病（T2DM）患者。在临床研究中，卡格列净显著降低糖化血红蛋白（A1C）、体重和血压，并且总体耐受性良好，低血糖风险没有增加。观察到的最常见不良反应是生殖器真菌感染、尿路感染和尿量增加。接受卡格列净治疗的女性中约10%发生生殖器真菌感染，而接受安慰剂治疗的为3%；有既往病史的女性风险更高。接受卡格列净治疗的女性中约9%报告有尿路感染，而接受安慰剂治疗的为7%。大多数不良事件的强度被认为是轻度至中度，对标准治疗有反应。卡格列净治疗对患有T2DM的女性（和男性）有效且总体耐受性良好。
